You are here:
Home
NICE Guidance
Conditions and diseases
Digestive tract conditions
Inflammatory bowel disease
Vedolizumab for treating moderately to severely active Crohn's disease in people 2 to 17 years [TSID12312]
Topic prioritisation
Project information
Project documents
29078-Vedolizumab-for-Crohns-Disease-V1.0-OCT2025-NON-CONF.pdf
Back to top